MK-677 Dosage Guide UK: Oral Administration, Timing & Safety Monitoring

MK-677 (ibutamoren) is a non-peptide, orally active growth hormone secretagogue receptor (GHSR) agonist — meaning it binds to the same receptor as ghrelin and stimulates the pituitary gland to release growth hormone.

Unlike injectable peptides such as CJC-1295 or Ipamorelin, MK-677 is taken orally as a capsule or liquid and has a substantially longer half-life of approximately 24 hours — meaning a single daily dose maintains sustained GH and IGF-1 elevation throughout the day.

Key pharmacological properties: - Oral bioavailability: Approximately 60–70% — substantially higher than most peptide compounds (which are degraded by gastric enzymes) - Half-life: ~24 hours (allowing once-daily dosing) - Mechanism: Ghrelin mimetic — activates GHSR-1a receptors in the pituitary and hypothalamus - Does not suppress the hypothalamic-pituitary-gonadal (HPG) axis — unlike anabolic steroids

Research findings: - Studies have demonstrated significant IGF-1 elevation sustained over 12+ months in elderly and GH-deficient populations - Research in elderly subjects showed increases in lean body mass and reduced fat mass with MK-677 administration - Some research has examined MK-677 in the context of muscle wasting, osteoporosis, and sleep quality (due to GH's role in slow-wave sleep)

Important context: MK-677 is a research compound, not an approved medication in the UK. It has not completed phase 3 clinical trials for any indication. Its long-term safety profile in healthy individuals is not fully established.

*This guide is for educational purposes only and does not constitute medical advice.*

MK-677 is typically supplied as oral capsules (10mg or 25mg) or as a liquid solution. The dose range used in research literature spans 10–25mg per day, with different dose ranges associated with different research objectives.

Dose range overview:

10mg/day (low dose): - Used in some elderly and frailty research as a starting or maintenance dose - Lower incidence of side effects (particularly water retention and increased appetite) - IGF-1 elevation is meaningful but more modest than at higher doses - A reasonable starting point for new research subjects to assess individual response and tolerance

20–25mg/day (standard research dose): - The dose range used in most published clinical research - The Merck-sponsored phase 2 trials (which generated much of the foundational MK-677 human data) primarily used 25mg/day - Associated with greater IGF-1 elevation and more pronounced effects on body composition markers in research contexts - Also associated with more pronounced side effects, particularly increased appetite and water retention

Dose forms: - Capsules: Most convenient; typically 10mg or 25mg per capsule - Liquid solution: Allows flexible dosing; requires careful measurement with an oral syringe

Does dose timing matter for oral MK-677? Yes — see the following section on timing. The oral route does not eliminate the relevance of timing, as GH secretion still follows diurnal patterns.

*Dose information is based on published clinical research. MK-677 is not an approved UK medication and should only be used in authorised research contexts.*

Despite MK-677's long half-life (which means blood levels remain relatively stable throughout the day regardless of timing), bedtime administration remains the most commonly recommended approach in research protocols.

Rationale for bedtime dosing:

1. Amplification of the nocturnal GH pulse: The body's largest GH secretion event occurs during slow-wave sleep. Administering a GH secretagogue before sleep synchronises pharmacological stimulation with the natural GH rhythm, potentially producing an additive or synergistic GH response.

2. Appetite management: One of MK-677's most consistent side effects is significantly increased appetite — a consequence of its ghrelin-mimetic mechanism. Taking MK-677 at bedtime means this appetite stimulation occurs during sleep, reducing the practical impact on daytime eating behaviour.

3. Water retention timing: Some users and researchers note that taking MK-677 before bed allows oedematous (fluid retention) effects to partially resolve overnight before morning activity.

Alternative timing considerations: - Morning dosing: Some research protocols use morning administration; the 24-hour half-life means IGF-1 elevation is maintained throughout the day regardless of timing - Fasted vs fed: Unlike injectable GHRH/GHRP combinations, MK-677 can be taken with or without food — gastric acid does not degrade it as it would a peptide. However, taking it in a carbohydrate-rich fed state may slightly blunt the immediate GH response

Practical recommendation in research protocols: Bedtime dosing is the most widely used timing convention and offers practical side-effect management advantages.

One of the most clinically important aspects of MK-677 research is its effect on insulin sensitivity and fasting glucose. This is not a minor consideration — it is a monitoring requirement for responsible research practice.

Why MK-677 affects blood glucose: Growth hormone has a well-established effect of reducing insulin sensitivity (increasing insulin resistance). As MK-677 chronically elevates GH levels, sustained exposure can result in: - Elevated fasting blood glucose levels - Impaired glucose tolerance - Compensatory hyperinsulinaemia (the pancreas produces more insulin to overcome resistance) - In susceptible individuals with pre-diabetic tendencies, MK-677 could potentially accelerate progression towards type 2 diabetes

Published research findings: Some clinical studies with MK-677 have reported statistically significant increases in fasting glucose and HbA1c in research subjects, particularly at the 25mg/day dose over extended periods.

Monitoring protocol recommendations:

• •Baseline blood glucose: Measure fasting glucose (and ideally HbA1c) before commencing any MK-677 research
• •Monthly monitoring: Check fasting glucose monthly during extended research periods
• •Home glucometer: A simple, inexpensive home blood glucose meter allows regular tracking without clinic visits
• •Warning signs: Excessive thirst, frequent urination, unexplained fatigue, or blurred vision warrant prompt medical review

Who should not participate in MK-677 research: - Individuals with type 1 or type 2 diabetes - Those with impaired fasting glucose or pre-diabetes - Anyone with a family history of type 2 diabetes without prior glucose tolerance testing

*Blood glucose effects are a well-documented characteristic of MK-677 in clinical research. Any research subject experiencing glucose abnormalities should cease administration and seek medical advice.*

Beyond blood sugar, responsible MK-677 research practice requires awareness of several other physiological effects and monitoring considerations.

Water retention (oedema): Water retention is one of the most commonly reported effects in both clinical research and community experience with MK-677. It is thought to result from: - GH-mediated aldosterone stimulation, causing sodium and water retention - Soft tissue remodelling associated with elevated IGF-1

Managing water retention: - Reduce dietary sodium — salt intake directly amplifies fluid retention - Ensure adequate hydration — paradoxically, adequate water intake can help reduce oedema - Lower the dose: At 10mg/day, water retention is generally much less pronounced than at 25mg/day - Be aware that apparent weight gain in early MK-677 use often reflects fluid, not fat or muscle - Water retention typically resolves within 2–4 weeks of cessation

Liver function monitoring: MK-677 is not a 17-alpha-alkylated compound (unlike some oral anabolic steroids) and is not considered hepatotoxic based on available research. Nevertheless, standard responsible research practice includes: - Baseline liver function tests (LFTs): ALT, AST, GGT, bilirubin - Mid-cycle and end-of-cycle LFTs: Particularly for research periods exceeding 12 weeks

Other monitoring considerations: - Prolactin: Some research subjects report elevated prolactin; a baseline and mid-cycle check is prudent - Cortisol: Unlike some earlier GHRPs, ibutamoren has minimal effect on cortisol, but monitoring is reasonable in longer research periods

Numbness and tingling: Carpal tunnel-like symptoms (tingling in the hands and wrists) have been reported in some research contexts, thought to relate to fluid accumulation in the carpal tunnel. Dose reduction typically resolves this.

*This guide is for educational purposes only. MK-677 is a research compound, not an approved UK medication. All research use should be conducted responsibly with appropriate safety monitoring.*